Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Immutep’s phase 3 failure for immunotherapy surprises analysts, sinks stock

Immutep’s phase 3 failure for immunotherapy surprises analysts, sinks stock

  • March 13, 2026

Immutep and the Australian biotech’s investors have been caught off guard by the unexpected failure of its LAG-3 candidate in a phase 3 study.

Leave A Comment

Fields (*) Mark are Required